Showing results (1-10 of 247) with videos related to

Sort By:
Pageof 25
Clinical Lymphoma, Myeloma & Leukemia|April 15, 2026
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 TrialFjoralba Kristo, Flora Mazerolle, Thibaud Alin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2025
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphomaMarie Lommen, Jasmin J Weindler, Janina Jablonski, et al.
Leukemia & Lymphoma|December 4, 2018
Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study GroupStefanie Kreissl, Helen Goergen, Horst Müller, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2023
Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study GroupJustin Ferdinandus, Lutz van Heek, Katrin Roth, et al.
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategiesAndreas Draube, Karolin Behringer, Volker Diehl
Hematology/Oncology Clinics of North America|November 30, 2013
Early intensification treatment approach in advanced-stage Hodgkin lymphomaPeter Borchmann
European Journal of Haematology. Supplementum|July 13, 2005
Female fertility after cytotoxic therapy--protection of ovarian function during chemotherapy of malignant and non-malignant diseasesVerena Mattle, Karolin Behringer, Andreas Engert, et al.
Frontiers in Oncology|June 11, 2021
Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients - An Analysis of GHSG HD14- and HD17-PatientsJohannes Rosenbrock, Andrés Vásquez-Torres, Horst Mueller, et al.
Pageof 25